Roche Holding Balance Sheet Health

Financial Health criteria checks 3/6

Roche Holding has a total shareholder equity of CHF32.9B and total debt of CHF34.4B, which brings its debt-to-equity ratio to 104.8%. Its total assets and total liabilities are CHF95.8B and CHF62.9B respectively. Roche Holding's EBIT is CHF18.0B making its interest coverage ratio 22.3. It has cash and short-term investments of CHF8.8B.

Key information

104.8%

Debt to equity ratio

CHF 34.44b

Debt

Interest coverage ratio	22.3x
Cash	CHF 8.81b
Equity	CHF 32.88b
Total liabilities	CHF 62.91b
Total assets	CHF 95.79b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: RO's short term assets (CHF33.6B) exceed its short term liabilities (CHF26.6B).

Long Term Liabilities: RO's short term assets (CHF33.6B) do not cover its long term liabilities (CHF36.3B).

Debt to Equity History and Analysis

Debt Level: RO's net debt to equity ratio (78%) is considered high.

Reducing Debt: RO's debt to equity ratio has increased from 63.1% to 104.8% over the past 5 years.

Debt Coverage: RO's debt is well covered by operating cash flow (46.8%).

Interest Coverage: RO's interest payments on its debt are well covered by EBIT (22.3x coverage).

Balance Sheet

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 14:58
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Roche Holding AG is covered by 59 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research

Roche Holding Balance Sheet Health

Financial Health criteria checks 3/6

Key information

Recent financial health updates

Recent updates

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran